Vaxcyte (PCVX): Can Shares Reach the $110 Target After the +50% Move on VAX-31 Data?
Key Takeaways
- The $110 central target is the arithmetic mean of the verified analyst price targets reviewed, not a single firm's forecast.
- Following positive OPUS-1 Phase 3 data for VAX-31, shares jumped to a new 52-week high around $87–$89, requiring roughly a 26% gain to reach $110.
- The analyst range is unusually wide, from about $67 to $163, reflecting divergent views on market share, approval timing, and dilution.
- The strongest support comes from best-in-class VAX-31 immunogenicity data and a large, growing pneumococcal vaccine market.
- The biggest risks are execution, a lengthy timeline to commercialization (BLA filing targeted for the first half of 2028), competition, and a rich valuation with no current revenue.
What the Analyst Price Targets Actually Show
This is a stock with extensive coverage, and the $110 figure is the average of the individual analyst price targets reviewed, rounded from a calculated mean near $109.67. The low-to-high range is wide, spanning roughly $67 to $163. At the bullish end, Mizuho carries a $163 target, and Jefferies' Roger Song called the data a "blue-sky" scenario while maintaining a $146 target. Guggenheim's Seamus Fernandez raised his target to $125 from $116 after the readout, keeping a Buy rating and Top Pick designation. Bank of America trimmed its target to $130 from $133 in late September, while Needham reiterated $110. More cautious voices sit well below that. Goldman Sachs has a neutral-leaning $67 target, with BTIG near $89, Leerink Partners around $82, and TD Cowen near $75. The disagreement largely reflects different assumptions about how much of the adult pneumococcal market VAX-31 can capture against incumbents from Pfizer and Merck, and how much future equity dilution will weigh on per-share value. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Where the Stock Stands Now and the Path Ahead
The latest verified price sits around $87 after the OPUS-1 topline readout, versus a prior close near $56. Reaching the $110 target implies a further gain of about 26%, a substantial move for a clinical-stage biotech that has already repriced sharply in a single session. Unlike a profitable company whose path can be modeled on earnings, Vaxcyte's stock forecast rests almost entirely on clinical and regulatory milestones. VAX-31 met all prespecified co-primary immunogenicity endpoints in adults 50 and older, showing noninferiority across shared serotypes and superiority for several unique serotypes. Management now plans a Biologics License Application (BLA) submission in the first half of 2028, with OPUS-2 and OPUS-3 results expected in the first half of 2027. From what I see, the technical breakout adds another layer worth monitoring closely.
Factors That Could Drive Shares Toward the Target
The clearest support is the quality of the data itself. Analysts described the readout as "near best-case," removing a major de-risking event for the lead program and validating the company's carrier-sparing conjugation platform. VAX-31's broad serotype coverage positions it as a potential best-in-class competitor in an adult pneumococcal vaccine market that analysts describe as worth billions and still growing. A strong balance sheet, with over $1 billion in cash reported in recent quarters, provides runway through the next clinical and regulatory steps. Upward earnings-estimate revisions and raised targets from firms like Guggenheim signal rising conviction in the commercial opportunity. One thing that stands out is how the platform technology could extend beyond this single candidate.
Risks That Could Keep the Target Out of Reach
Vaxcyte is pre-revenue, generating losses as it funds a broad pipeline, so the valuation is almost entirely forward-looking. Dilution from future capital raises could pressure per-share value, a point reflected in some lower targets. Full safety and immunogenicity details from OPUS-1, as well as the infant studies and the OPUS-2 and OPUS-3 trials, still carry binary risk. Competition is entrenched: Pfizer's Prevnar 20 and Merck's Capvaxive are marketed products with established commercial infrastructure. Finally, the long runway to a 2028 BLA filing and a launch now expected around 2029 (per BofA's note) leaves substantial execution and regulatory risk that could compress the multiple. I’m watching this closely because any slippage on timelines could shift the entire outlook.
Technical Levels Worth Noting
The surge established a new 52-week high near $89, breaking decisively above the prior ceiling around $65. Before the readout, the 50-day moving average sat near $58.67 and the 200-day near $56.18, levels now far below the current price. Mizuho suggested the stock could trade in a $90–$100 range near term, so $100 looms as a psychological resistance level ahead of the $110 target, while the old $65 breakout zone may act as a distant support area on any pullback. Using Tickeron’s AI Trend Prediction Engine gave me additional context on how momentum might evolve from here.
Key Items to Watch Over Time
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms may differ and the company's value drivers extend well beyond that window. Key items to watch include the full OPUS-1 safety and immunogenicity presentation, the OPUS-2 and OPUS-3 readouts expected in the first half of 2027, infant study updates, BLA submission timing, and any further target revisions or financing announcements.
AI Daily Buy/Sell Signals
In my research process, Tickeron's AI Daily Buy/Sell Signals have become a useful way to track momentum shifts in names like this one. The tool applies artificial intelligence to monitor thousands of stocks and ETFs in real time, generating Buy, Sell, or Hold signals based on technical behavior and changing market conditions. For a catalyst-driven stock such as Vaxcyte, it helps surface opportunities and monitor positions more efficiently than manual review alone. I find it fits naturally alongside traditional analysis when evaluating volatile clinical-stage names.
Final Assessment
The $110 target is the average of a wide analyst range, from roughly $67 to $163, and sits about 26% above the post-surge price near $87. The bull case rests on best-in-class VAX-31 data and a large, growing pneumococcal market, while the bear case emphasizes a long path to revenue, entrenched competition, dilution, and a forward-looking valuation. With the stock already repricing sharply, reaching $110 depends less on the headline data and more on successful execution through additional trials, regulatory filing, and eventual commercialization. No outcome is guaranteed, and the wide target range underscores genuine uncertainty.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
PCVX in upward trend: price rose above 50-day moving average on October 05, 2026
PCVX moved above its 50-day moving average on October 05, 2026 date and that indicates a change from a downward trend to an upward trend. In 35 of 41 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 64 cases where PCVX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on PCVX as a result. In 65 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for PCVX just turned positive on October 05, 2026. Looking at past instances where PCVX's MACD turned positive, the stock continued to rise in 42 of 51 cases over the following month. The odds of a continued upward trend are 82%.
Following a +31.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where PCVX advanced for three days, in 224 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The 10-day moving average for PCVX crossed bearishly below the 50-day moving average on September 25, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PCVX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
PCVX broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PCVX entered a downward trend on October 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 53 (best 1 - 100 worst), indicating steady price growth. PCVX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.144) is normal, around the industry mean (26.780). P/E Ratio (12.594) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 67 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PCVX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in development of vaccines for infectious diseases
Industry Biotechnology
Advertisement